ReviewBiochemistry and biophysics reports2026
A different MAPK, ERK5 plays a critical role in cell specification and differentiation.
Review in Biochemistry and biophysics reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Article
- Novel 3‑Aza-Bicyclo[3.3.0]octane Compounds as ERK5 Inhibitors for Treating Cancer.ACS medicinal chemistry letters · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extracellular signal-regulated kinase 5 (ERK5), a unique member of the mitogen-activated protein kinase (MAPK) family, plays a critical role in cell fate determination due to its distinct structure. This review aims to systematically summarize the central role of the ERK5 signaling pathway in cell specification and differentiation. Substantial evidence indicates that, by integrating diverse extracellular signals and regulating key transcription factors, ERK5 precisely controls the fate specification and differentiation of various cell types, including stem cells, neural cells, immune cells, endothelial cells, and osteoblasts. Furthermore, aberrant MEK5/ERK5 signaling is closely linked to the pathogenesis and progression of various diseases, particularly cancer, and is associated with drug resistance. By delineating the signaling mechanisms and functions of ERK5 across different cellular contexts, this review seeks to deepen the understanding of its physiological and pathological activities and to provide new potential targets and insights for regenerative medicine and cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.